ArticleVaccine2018
Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study.
Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Minimum Data Set and Metadata for Active Vaccine Safety Surveillance: Systematic Review.JMIR public health and surveillance · 2025Pooled it
- Pooled it
- Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial.Emerging microbes & infections · 2023Trial
- Combating Immunization Misinformation: What's New?The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Article
- Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States.Expert review of vaccines · 2025Review
- Post-marketing safety study to evaluate pregnancy outcomes among recipients of hepatitis B vaccines.Human vaccines & immunotherapeutics · 2024Article
- Defining and reporting adverse events of special interest in comparative maternal vaccine studies: a systematic review.Vaccine: X · 2024Review
- Hepatitis B Vaccine: Four Decades on.Vaccines · 2024Review
- Effects of hepatitis B virus infection and strategies for preventing mother-to-child transmission on maternal and fetal T-cell immunity.Frontiers in immunology · 2023Review
- Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: A rapid review.Vaccine · 2021Review
- Protective vaccinations during pregnancy - adult Poles knowledge in this area.BMC public health · 2021Article
- Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review.medRxiv : the preprint server for health sciences · 2021Article
- The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations.American journal of obstetrics and gynecology · 2021Review
- Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination.Therapeutic advances in drug safety · 2021Article
- Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study.Vaccine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 1 country.
Funding
Abstract
introductionHepatitis B virus (HBV) infection acquired during pregnancy can pose a risk to the infant at birth that can lead to significant and lifelong morbidity. Hepatitis B vaccine (HepB) is recommended for anyone at increased risk for contracting HBV infection, including pregnant women. Limited data are available on the safety of HepB administration during pregnancy.
objectivesTo assess the frequency of maternal HepB receipt among pregnant women and evaluate the potential association between maternal vaccination and pre-specified maternal and infant safety outcomes.
methodsWe examined a retrospective cohort of pregnancies in the Vaccine Safety Datalink (VSD) resulting in live birth outcomes from 2004 through 2015. Eligible pregnancies in women aged 12-55 years who were continuously enrolled from 6 months pre-pregnancy to 6 weeks postpartum in VSD integrated health systems were included. We compared pregnancies with HepB exposure to those with other vaccine exposures, and to those with no vaccine exposures. High-risk conditions for contracting HBV infection were identified up to one-year prior to or during the pregnancy using ICD-9 codes. Maternal and fetal adverse events were also evaluated according to maternal HepB exposure status.
resultsAmong over 650,000 pregnancies in the study period, HepB was administered at a rate of 2.1 per 1000 pregnancies (n = 1399), commonly within the first 5 weeks of pregnancy. Less than 3% of the HepB-exposed group had a high-risk ICD-9 code indicating need for HepB; this was similar to the rate among HepB unvaccinated groups. There were no significant associations between HepB exposure during pregnancy and gestational hypertension, gestational diabetes, pre-eclampsia/eclampsia, cesarean delivery, pre-term delivery, low birthweight or small for gestational age infants.
conclusionsMost women who received maternal HepB did not have high-risk indications for vaccination. No increased risk for the adverse events that were examined were observed among women who received maternal HepB or their offspring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.